

1 **Delays in COVID-19 Diagnosis and Hospitalization and Outcomes — New York City, New**
2 **York, USA, October 2020–November 2021**

3 Laura E. Graf *, MPH, Eric R. Peterson, MPH, Jennifer Baumgartner, MSPH, Anne Fine, MD,¹

4 Corinne N. Thompson, PhD,² Kathleen Blaney, MPH, RN, Sharon K. Greene, PhD, MPH

5 Author affiliations: New York City Department of Health and Mental Hygiene, Queens, New

6 York, USA (L.E. Graf, E.R. Peterson, J. Baumgartner, A. Fine, C.N. Thompson, K. Blaney, S.K.

7 Greene)

8 ¹Current affiliation: Council of State and Territorial Epidemiologists, Atlanta, Georgia, USA

9 ²Current affiliation: NYU Langone Health, New York, New York, USA

10 *Corresponding Author: lgraf@health.nyc.gov

11

12 Running Title: Delays in COVID-19 Diagnosis and Hospitalization

13 MeSH Keywords: COVID-19, SARS-CoV-2, Pandemics, Epidemiology, Early diagnosis,

14 Treatment outcome, Patient admission, Length of stay

15 **Abstract:**

16 COVID-19 patients diagnosed ≥ 3 days after symptom onset had increased odds of
17 hospitalization. The 75th percentile for diagnosis delay was 5 days for residents of low-privilege
18 areas and Black and Hispanic people diagnosed before SARS-CoV-2 Delta predominance,
19 compared with 4 days for other patients, indicating inequities in prompt diagnosis.

20 Delays in testing or care-seeking for certain respiratory infections can impede access to
21 potentially life-saving treatments (1, 2), contributing to worse outcomes, including
22 hospitalization and death (3). Reasons for delayed care-seeking include prohibitive costs, lack of
23 access to healthcare services, and stigmatization (4, 5). However, little is known about the impact
24 of care-seeking delays on COVID-19 outcomes in the United States (6, 7). We assessed
25 relationships between delays in diagnosis of and hospitalization with COVID-19 and severe
26 outcomes.

27 **The Study**

28 The study population included NYC residents symptomatic with COVID-19-like illness
29 and diagnosed with COVID-19 via a positive SARS-CoV-2 molecular or antigen test or
30 hospitalized after exposure to a confirmed COVID-19 case during October 1, 2020–November
31 30, 2021. We hypothesized that increased time between symptom onset and diagnosis or
32 hospitalization was associated with worse outcomes; accordingly, our exposures were time to
33 diagnosis (days from symptom onset to diagnosis) and time to hospitalization (days from
34 symptom onset to hospital admission), each classified into quintiles. COVID-19 symptoms and
35 symptom onset date were collected through case investigation. Diagnosis date was defined as the
36 earlier of specimen collection date of the first positive test or hospital admission date. Patients
37 with an onset date following their diagnosis or admission date were excluded, effectively
38 excluding healthcare-associated cases. Patients with a diagnosis or admission date >21 days after
39 onset were excluded because true long delays could not be distinguished from data entry errors.
40 Our outcomes of interest were hospitalization, death, and length of hospital stay. A COVID-19
41 hospitalization was defined as a hospital admission +/- 14 days from a positive SARS-CoV-2
42 molecular or antigen test or hospitalization at the time of death from COVID-19. A COVID-19

43 death was defined as 1) occurring within +/- 30 days of a positive COVID-19 molecular test and
44 not from external causes or 2) a cause of death of COVID-19 on the death certificate and a
45 positive COVID-19 molecular test. Length of stay was defined as the number of days from
46 hospital admission to discharge and was dichotomized at the median (>5 vs. ≤5 days) (Appendix:
47 Statistical Analysis). The NYC Department of Health and Mental Hygiene's Institutional Review
48 Board determined this work was exempt human subjects research for which consent was not
49 required.

50 Of 864,880 COVID-19 cases diagnosed during October 1, 2020–November 31, 2021,
51 454,010 patients and 26,462 hospitalized patients were eligible for analysis (Figure 1). Relative
52 to patients diagnosed one day after symptom onset and adjusting for sociodemographic
53 confounders, patients diagnosed the same day as symptom onset (adjusted odds ratio [aOR]:
54 1.31; 95% confidence interval [CI], 1.25, 1.37), 3–4 days after symptom onset (aOR: 1.08; 95%
55 CI, 1.03, 1.13), and 5–21 days after symptom onset (aOR: 1.36; 95% CI, 1.31, 1.42) had
56 increased odds of hospitalization (Table 1). Patients diagnosed the same day as their symptom
57 onset also had higher odds of death (aOR: 1.21; 95% CI, 1.06, 1.38) (Table 1).

58 Among hospitalized patients, those hospitalized 11–21 days after symptom onset had
59 decreased odds of death compared with patients hospitalized 0–2 days after symptom onset
60 (aOR: 0.73; 95% CI, 0.63, 0.83) (Table 2). Patients hospitalized 6–7 days after symptom onset
61 had increased risk of hospital stay lasting >5 days (adjusted relative risk: 1.09; 95% CI, 1.04,
62 1.14) (Table 2). For patients diagnosed or hospitalized 1–5 days after symptom onset, diagnosis
63 or hospitalization during a monoclonal (mAb) antibody availability period (January 16–
64 November 30, 2021) relative to a prior period (October 1–December 15, 2020) was not
65 associated with improved outcomes (Appendix: Monoclonal Antibody Availability).

66 We assessed whether delays from symptom onset to diagnosis varied by race/ethnicity
67 and privilege measured by Index of Concentration at the Extremes (ICE) (8). Early in the study
68 period and before Delta variant predominance (October 2020–June 2021), Black and Hispanic
69 patients and patients in the two lowest quintiles of privilege had longer 75th percentiles for time
70 to COVID-19 diagnosis (5 days) compared with other patients (4 days) (Figure 2). Later in the
71 study period and during Delta variant predominance (July–November 2021), delay distributions
72 were the same for patients of all race/ethnicities and patients in the lowest four quintiles of
73 privilege. Among patients residing in the most privileged census tracts, the 75th percentile of
74 time to diagnosis decreased from 4 days to 3 days (Figure 2).

75 **Conclusions:**

76 Delayed COVID-19 diagnosis ≥ 3 days after symptom onset was associated with
77 increased odds of hospitalization, and hospitalization 6–7 days following symptom onset was
78 associated with longer hospital stays, suggesting delayed testing or care-seeking might contribute
79 to more severe outcomes. Early COVID-19 testing and diagnosis can ensure timely treatment
80 with appropriate therapies including mAb, antivirals, and steroids, which can improve prognosis
81 (9, 10). While we do not have treatment data, our findings are consistent with previous studies
82 that support early diagnosis and hospitalization of COVID-19 patients to prevent severe
83 outcomes (1, 11).

84 Risk of longer hospital stay was highest for patients hospitalized 6–7 days after symptom
85 onset, consistent with the period when COVID-19 disease severity often increases (12).
86 Conversely, risk of longer hospital stay and odds of death were decreased in patients hospitalized
87 11–21 days after symptom onset, perhaps indicating high-risk patients sought care earlier.
88 Patients diagnosed the same day as symptom onset had greater odds of both hospitalization and

89 death, potentially reflecting misclassification where patients were misreported as having
90 symptom onset on their diagnosis or admission date despite earlier symptom onset.

91 Black and Hispanic people and residents of low-privilege areas diagnosed before Delta
92 variant predominance experienced longer times to diagnosis, reflecting systemic racism
93 manifested through reduced access to testing and failure of healthcare systems to build trust (13,
94 14). In late 2020, NYC Test and Trace Corps deployed mobile testing units and patient
95 navigators to improve testing access in Task Force on Racial Inclusion and Equity (TRIE)
96 neighborhoods, selected based on health status, social inequities, living conditions, occupation,
97 and COVID-19 burden during wave 1 (15). The decrease in time to diagnosis among Black and
98 Hispanic people and residents of the least privileged census tracts over the study period might
99 reflect these targeted efforts to reduce testing inequities. Nevertheless, a decreased time to
100 diagnosis was also observed among patients residing in the most privileged census tracts,
101 indicating persistent inequities in COVID-19 testing access and resources. Sustained funding is
102 necessary to ensure equitable access to testing and care across all communities.

103 Our analysis has several limitations. First, we did not have data on symptom severity and
104 timing, which limited our ability to distinguish delays in care-seeking from slower illness
105 progression. Second, a portion of patients with symptom onset and diagnosis on the same day
106 could reflect recall bias or data entry errors during case investigations. Third, hospitalizations
107 were ascertained by matching to data sources including hospital databases and health information
108 exchanges and may be incomplete or reflect hospitalizations where SARS-CoV-2 infection was
109 an incidental diagnosis. Nevertheless, our study adds to the limited evidence on outcomes of
110 delays in COVID-19 care-seeking. Future studies should examine the causes of care-seeking
111 delays and inequities to inform messaging and illuminate opportunities to direct testing and

112 resources. In addition to vaccination, early care-seeking will be important in preventing severe
113 COVID-19 outcomes, especially as novel therapeutics emerge.

114 **Acknowledgements:**

115 The authors thank Mary Foote, MD for her guidance and all NYC Department of Health and
116 Mental Hygiene staff activated for the COVID-19 emergency response.

117 **Funding:**

118 The authors received no specific funding for this work beyond their usual salaries. SKG was
119 supported by the Public Health Emergency Preparedness Cooperative Agreement (grant No.
120 NU90TP922035-03-03), funded by the US Centers for Disease Control and Prevention (CDC).

121 **Conflicts of Interest:**

122 All authors have completed the ICMJE uniform disclosure form at
123 www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the
124 submitted work; no financial relationships with any organizations that might have an interest in
125 the submitted work in the previous three years; no other relationships or activities that could
126 appear to have influenced the submitted work.

127 **Biographical Sketch:**

128 Laura E. Graf is a surveillance analyst in the Bureau of Hepatitis, HIV, and Sexually Transmitted
129 Infections at the New York City Department of Health and Mental Hygiene, Queens, New York.
130 Her interests include infectious disease epidemiology and surveillance.

131 **References**

- 132 1. Alaa A, Qian Z, Rashbass J, Bengner J, van der Schaar M. Retrospective cohort study of
133 admission timing and mortality following COVID-19 infection in England. *BMJ Open*. 2020
134 Nov 23;10(11):e042712.
- 135 2. Weissman JS, Stern R, Fielding SL, Epstein AM. Delayed access to health care: risk
136 factors, reasons, and consequences. *Annals of internal medicine*. 1991 Feb 15;114(4):325-31.
- 137 3. Ahmed AE. Diagnostic delays in Middle East respiratory syndrome coronavirus patients
138 and health systems. *J Infect Public Health*. 2019 Nov - Dec;12(6):767-71.
- 139 4. Pujolar G, Oliver-Angles A, Vargas I, Vazquez ML. Changes in Access to Health
140 Services during the COVID-19 Pandemic: A Scoping Review. *Int J Environ Res Public Health*.
141 2022 Feb 3;19(3).
- 142 5. National Center for Health Statistics. Percentage of adults aged 18 and over who delayed
143 getting medical care due to cost in past 12 months, United States, 2019—2020. [cited 2022
144 February 24]; Available from:
145 https://wwwn.cdc.gov/NHISDataQueryTool/SHS_adult/index.html.
- 146 6. Zheng W, Kampfen F, Huang Z. Health-seeking and diagnosis delay and its associated
147 factors: a case study on COVID-19 infections in Shaanxi Province, China. *Sci Rep*. 2021 Aug
148 30;11(1):17331.
- 149 7. Muhrer JC. Risk of misdiagnosis and delayed diagnosis with COVID-19: A Syndemic
150 Approach. *Nurse Pract*. 2021 Feb 1;46(2):44-9.
- 151 8. Krieger N, Waterman PD, Spasojevic J, Li W, Maduro G, Van Wye G. Public Health
152 Monitoring of Privilege and Deprivation With the Index of Concentration at the Extremes. *Am J*
153 *Public Health*. 2016 Feb;106(2):256-63.

- 154 9. Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. Early antiviral treatment contributes to
155 alleviate the severity and improve the prognosis of patients with novel coronavirus disease
156 (COVID-19). *J Intern Med.* 2020 Jul;288(1):128-38.
- 157 10. Kow CS, Ramachandram DS, Hasan SS. The use of neutralizing monoclonal antibodies
158 and risk of hospital admission and mortality in patients with COVID-19: a systematic review and
159 meta-analysis of randomized trials. *Immunopharmacol Immunotoxicol.* 2022 Feb;44(1):28-34.
- 160 11. Gamboa-Cardenas RV, Barzola-Cerron S, Toledo-Neira D, Reategui-Sokolova C,
161 Pimentel-Quiroz V, Zevallos-Miranda F, et al. Predictors of hospitalization for COVID-19 in
162 patients with autoimmune rheumatic diseases: results from a community cohort follow-up. *Clin*
163 *Rheumatol.* 2021 Nov;40(11):4725-34.
- 164 12. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
165 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
166 *JAMA.* 2020 Mar 17;323(11):1061-9.
- 167 13. Egede LE, Walker RJ. Structural Racism, Social Risk Factors, and Covid-19 — A
168 Dangerous Convergence for Black Americans. *New England Journal of Medicine.*
169 2020;383(12):e77.
- 170 14. Ahmed A, Song Y, Wadhwa RK. Racial/Ethnic Disparities in Delaying or Not Receiving
171 Medical Care During the COVID-19 Pandemic. *J Gen Intern Med.* 2022 Apr;37(5):1341-3.
- 172 15. Jimenez J, Parra YJ, Murphy K, Chen AN, Cook A, Watkins J, et al. Community-
173 Informed Mobile COVID-19 Testing Model to Addressing Health Inequities. *J Public Health*
174 *Manag Pract.* 2022 Jan-Feb 01;28(Suppl 1):S101-S10.

Table 1. Days from COVID-19 symptom onset to diagnosis and odds of hospitalization and death, New York City, NY, USA, October 2020–November 2021

Days to diagnosis quintile	Total	Hospitalizations	Days to diagnosis and odds of hospitalization			
	No. (%)	No. (%)	OR (95% CI)	<i>p</i> value	aOR* (95% CI)	<i>p</i> value
Q1: 0	77,969 (17.2%)	4,967 (19.4%)	1.50 (1.44, 1.57)	<.0001	1.31 (1.25,1.37)	<.0001
Q2: 1	93,843 (20.7%)	4,071 (15.9%)	REF		REF	
Q3: 2	80,728 (17.8%)	3,588 (14.0%)	1.03 (0.98, 1.07)	0.28	0.96 (0.92,1.01)	0.0867
Q4: 3-4	99,128 (21.8%)	5,305 (20.7%)	1.25 (1.20, 1.30)	<.0001	1.08 (1.03, 1.13)	0.0007
Q5: 5-21	102,342 (22.5%)	7,707 (30.0%)	1.80 (1.73, 1.87)	<.0001	1.36 (1.31, 1.42)	<.0001
		Deaths	Days to diagnosis and odds of death			
		No. (%)	OR (95% CI)	<i>p</i> value	aOR* (95% CI)	<i>p</i> value
Q1: 0		550 (20.6%)	1.60 (1.41, 1.82)	<.0001	1.21 (1.06, 1.38)	0.0047
Q2: 1		415 (15.5%)	REF		REF	
Q3: 2		354 (13.2%)	0.99 (0.86, 1.14)	0.90	0.90 (0.77, 1.03)	0.1301
Q4: 3-4		558 (20.8%)	1.28 (1.12, 1.45)	0.0002	1.01 (0.89, 1.15)	0.8742
Q5: 5-21		800 (29.9%)	1.77 (1.58, 2.00)	<.0001	1.11 (0.98, 1.25)	0.1019

*Adjusted for age group, gender, borough of residence, and neighborhood poverty

Table 2. Days from COVID-19 symptom onset to hospitalization and odds of death and risk of length of stay >5 days*, New York City, NY, USA, October 2020–November 2021

Days to hospitalization quintile	Total	Deaths	Days to hospitalization and odds of death			
	No. (%)	No. (%)	OR (95% CI)	<i>p</i> value	aOR [†] (95% CI)	<i>p</i> value
Q1: 0-2	5,983 (22.6%)	638 (25.8%)	REF		REF	
Q2: 3-5	5,167 (19.5%)	542 (21.9%)	0.98 (0.87, 1.11)	0.77	1.04 (0.91, 1.18)	0.5819
Q3: 6-7	3,973 (15.0%)	390 (15.8%)	0.91 (0.80, 1.04)	0.17	1.03 (0.90, 1.19)	0.6368
Q4: 8-10	5,943 (22.5%)	495 (20.0%)	0.76 (0.67, 0.86)	<.0001	0.90 (0.80, 1.03)	0.1220
Q5: 11-21	5,396 (20.4%)	410 (16.6%)	0.69 (0.61, 0.79)	<.0001	0.73 (0.63, 0.83)	<.0001
		LOS [‡] >5 days	Days to hospitalization and risk of LOS [‡] >5 days			
		No. (%)	RR (95% CI)	<i>p</i> value	aRR [†] (95% CI)	<i>p</i> value
Q1: 0-2	4,632 (22.1%)	2,160 (22.3%)	REF		REF	
Q2: 3-5	4,037 (19.2%)	1,904 (19.7%)	1.01 (0.97, 1.06)	0.6207	1.01 (0.97, 1.05)	0.6473
Q3: 6-7	3,172 (15.1%)	1,583 (16.3%)	1.07 (1.02, 1.12)	0.0043	1.09 (1.04, 1.14)	0.0002
Q4: 8-10	4,827 (23.0%)	2,231 (23.0%)	0.99 (0.95, 1.03)	0.6873	1.03 (0.98, 1.07)	0.2425
Q5: 11-21	4,333 (20.6%)	1,809 (18.7%)	0.90 (0.85, 0.94)	<.0001	0.90 (0.86, 0.94)	<.0001

*5 days represents the median length of stay for patients hospitalized with COVID-19 in this sample

[†]Adjusted for age group, gender, borough of residence, and neighborhood poverty

[‡]Length of stay

175 **Appendix, Delays in COVID-19 Diagnosis and Hospitalization and Outcomes — New York**
176 **City, New York, USA, October 2020–November 2021**

177 **Statistical Analysis**

178 Logistic regression was used to assess associations between time to diagnosis and
179 hospitalization or death. Associations between time to hospitalization and length of stay were
180 modeled using log-binomial regression as the outcome of length of stay >5 days was not rare (1).
181 All models were adjusted for age group (<5, 5–14, 15–24, 25–44, 45–64, and ≥65 years-old),
182 gender, borough of residence, and neighborhood poverty based on census tract per the American
183 Community Survey 2015–2019 as these covariates are known to be associated with both
184 outcome and exposure (2-4). Race/ethnicity was initially considered as an additional confounder
185 but was excluded as a covariate from final models because of high missingness (13.0%).
186 To assess variation in diagnosis delays, we stratified the time between symptom onset and
187 diagnosis by race/ethnicity and privilege measured by Index of Concentration at the Extremes
188 (ICE) (5). ICE was based on patient census tract of residence and categorized into quintiles from
189 least privileged (highest prevalence of low-income (<\$25,000), people of color households) to
190 most privileged (highest prevalence of high-income (≥\$100,000), non-Hispanic white
191 households), per the American Community Survey 2015–2019. Of 454,010 patients in the
192 analytical dataset, 59,151 (13.0%) had missing race/ethnicity, and 56 (0.01%) were missing a
193 census tract and could not be assigned an ICE quintile.

194 Data were frozen on April 5, 2022, allowing 4 months for ascertainment of
195 hospitalizations and deaths for patients diagnosed through the end of the study period, November
196 30, 2021. Only patients diagnosed starting October 1, 2020 were included, as this is when
197 symptom onset date became reliable through case investigation. Prior to October 1, 2020, if

198 symptom onset date was missing, it was populated by the first positive test date, and we did not
199 want to conflate these two dates. Statistical analyses were performed using SAS Enterprise
200 Guide, version 7.1 (SAS Institute).

201 **Monoclonal Antibody Availability**

202 We further explored associations between the exposures of time to diagnosis and time to
203 hospitalization with the outcomes of hospitalization and of death relative to monoclonal antibody
204 (mAb) therapy availability in NYC. Patients were classified into either the pre-mAb period or the
205 mAb availability period. Patient-level mAb data was not available, so mAb availability was
206 considered a proxy of mAb use. mAb therapy availability in NYC increased exponentially
207 between the weeks of December 16, 2020 and January 13, 2021 before reaching a high plateau of
208 approximately 700 mAb treatments administered per week. mAb use decreased as cases
209 decreased between May–July 2021, before increasing to a peak of approximately 2,000 mAb
210 treatments administered per week during the SARS-CoV-2 Delta variant wave (New York City
211 Department of Health and Mental Hygiene, unpub. data). Accordingly, we defined the pre-mAb
212 therapy availability period as October 1, 2020–December 15, 2020 and the mAb availability
213 period as January 16, 2021–November 30, 2021. Patients diagnosed during December 16, 2020–
214 January 15, 2021 were excluded to account for delays in the rollout of mAb therapy. Only
215 patients with a time to diagnosis of 1–5 days were included as the CDC recommends monoclonal
216 antibodies be administered within 10 days of symptom onset, and a secondary analysis that
217 included patients with a time to diagnosis ≤ 10 days yielded insignificant estimates of the odds of
218 hospitalization and death for patients with a time to diagnosis or hospitalization > 5 days.

219 253,926 patients met the criteria for inclusion in the mAb availability analysis. Compared
220 with patients diagnosed 1–5 days after symptom onset in the pre-mAb availability period, odds

221 of hospitalization were increased for patients diagnosed during the mAb availability period
222 (aOR: 1.09, 95% CI, 1.04, 1.15). Odds of death were increased during the mAb availability
223 period relative to the pre-mAb availability period among patients hospitalized (aOR: 1.42, 95%
224 CI, 1.12, 1.79), but not diagnosed (aOR: 1.15, 95% CI, 0.98, 1.34), 1–5 days after symptom
225 onset (Appendix Table).

226 These results contradicted our hypothesis that patients diagnosed during the mAb
227 availability period would have decreased odds of hospitalization and death. This discrepancy
228 could be attributed to our lack of patient-level data on mAb treatment, so diagnosis and
229 hospitalization during the mAb availability period may not reflect mAb use. Also, more severe
230 SARS-CoV-2 variants, including the Delta variant, emerged during the mAb availability period
231 (6). The circulation of these variants may have resulted in increased odds of hospitalization and
232 death in this population even with the availability of mAb. Future studies should include patient-
233 level mAb treatment information.

234 **References**

- 235 1. Skov T, Deddens J, Petersen MR, Endahl L. Prevalence proportion ratios: estimation and
236 hypothesis testing. *Int J Epidemiol.* 1998 Feb;27(1):91-5.
- 237 2. Muhrer JC. Risk of misdiagnosis and delayed diagnosis with COVID-19: A Syndemic
238 Approach. *Nurse Pract.* 2021 Feb 1;46(2):44-9.
- 239 3. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors
240 Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US.
241 *JAMA Intern Med.* 2020 Nov 1;180(11):1436-47.
- 242 4. Zheng W, Kampfen F, Huang Z. Health-seeking and diagnosis delay and its associated
243 factors: a case study on COVID-19 infections in Shaanxi Province, China. *Sci Rep.* 2021 Aug
244 30;11(1):17331.
- 245 5. Krieger N, Waterman PD, Spasojevic J, Li W, Maduro G, Van Wye G. Public Health
246 Monitoring of Privilege and Deprivation With the Index of Concentration at the Extremes. *Am J*
247 *Public Health.* 2016 Feb;106(2):256-63.
- 248 6. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al.
249 Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2)
250 compared with alpha (B.1.1.7) variants of concern: a cohort study. *Lancet Infect Dis.* 2022
251 Jan;22(1):35-42.

Appendix Table. Days from symptom onset to diagnosis and hospitalization and odds of hospitalization and death by monoclonal antibody


		Total	Hospitalizations	Days to diagnosis and odds of hospitalization by mAb* availability			
Days to diagnosis	mAb availability	No. (%)	No. (%)	OR (95% CI)	<i>p</i> value	aOR [†] (95% CI)	<i>p</i> value
1 to 5	No	40,318 (15.9%)	1,948 (15.8%)	REF		REF	
1 to 5	Yes	213,608 (84.1%)	10,415 (84.2%)	1.01 (0.96, 1.06)	0.7063	1.09 (1.04, 1.15)	0.0009
		Deaths		Days to diagnosis and odds of death by mAb availability			
Days to diagnosis	mAb availability	No. (%)		OR (95% CI)	<i>p</i> value	aOR [†] (95% CI)	<i>p</i> value
1 to 5	No	194 (15.5%)		REF		REF	
1 to 5	Yes	1,059 (84.5%)		1.03 (0.88, 1.20)	0.7042	1.15 (0.98, 1.34)	0.0787
		Total	Deaths	Days to hospitalization and odds of death by mAb availability			
Days to hospitalization	mAb availability	No. (%)	No. (%)	OR (95% CI)	<i>p</i> value	aOR [†] (95% CI)	<i>p</i> value
1 to 5	No	1,072 (14.6%)	92 (12.0%)	REF		REF	
1 to 5	Yes	6,278 (85.4%)	672 (88.0%)	1.28 (1.02, 1.60)	0.0359	1.42 (1.12, 1.79)	0.0039

therapy availability, New York City, NY, USA, October 2020–November 2021

*monoclonal antibody

†Adjusted for age group, gender, borough of residence, and neighborhood poverty


Figure 1. Flowchart of inclusion in analyses of delays in COVID-19 diagnosis and hospitalization, New York City, NY, USA, October 2020–November 2021



*New York City Office of Chief Medical Examiner

†Age group, gender, borough of residence, and neighborhood poverty

Figure 2. Boxplots* of delays from COVID-19 symptom onset to diagnosis by Index of Concentration at the Extremes and race/ethnicity by timing of diagnosis relative to SARS-CoV-2 Delta variant predominance,[†] New York City, NY, USA, October 2020–November 2021



*The middle line in each box represents the median time to diagnosis. The span of each box is the interquartile range (IQR), from the 25th percentile of time to diagnosis to the 75th percentile. The bottom whisker is the minimum value of time to diagnosis, and the top whisker is 1.5 times the IQR. Patients with time to diagnosis <0 days or >21 days were excluded.

[†]Delta variant predominance = No defined as diagnosis during October 1, 2020–June 30, 2021. Delta variant predominance = Yes defined as diagnosis during July 1, 2021–November 30, 2021.